2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one has been researched along with Angioma in 1 studies
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source
Angioma: A vascular anomaly due to proliferation of blood or lymphatic vessels that forms a tumor-like mass. Vessels in the angioma may or may not be dilated.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The current study demonstrated the antiangiogenic properties of propranolol in vitro and that the drug was able to induce the regression of hemangioma cells via the inhibition of cell cycle progression, invasion, and tube formation, concomitantly with decreased NO and VEGF levels through the down-regulation of the PI3K/Akt/eNOS/VEGF pathway." | 7.81 | Propranolol induces regression of hemangioma cells via the down-regulation of the PI3K/Akt/eNOS/VEGF pathway. ( Gao, Y; Guo, ZT; Huang, Q; Li, P; Pan, WK, 2015) |
| "The current study demonstrated the antiangiogenic properties of propranolol in vitro and that the drug was able to induce the regression of hemangioma cells via the inhibition of cell cycle progression, invasion, and tube formation, concomitantly with decreased NO and VEGF levels through the down-regulation of the PI3K/Akt/eNOS/VEGF pathway." | 3.81 | Propranolol induces regression of hemangioma cells via the down-regulation of the PI3K/Akt/eNOS/VEGF pathway. ( Gao, Y; Guo, ZT; Huang, Q; Li, P; Pan, WK, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pan, WK | 1 |
| Li, P | 1 |
| Guo, ZT | 1 |
| Huang, Q | 1 |
| Gao, Y | 1 |
1 other study available for 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one and Angioma
| Article | Year |
|---|---|
Propranolol induces regression of hemangioma cells via the down-regulation of the PI3K/Akt/eNOS/VEGF pathway.
Topics: Adrenergic beta-Antagonists; Angiogenesis Inhibitors; Cell Cycle Checkpoints; Cell Proliferation; Ce | 2015 |